World Journal of Nuclear Medicine

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 19  |  Issue : 2  |  Page : 93--98

Quality control and GMP synthesis of68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer


Majid Assadi1, Habibollah Dadgar2 
1 The Persian Gulf Nuclear Medicine Research Center; Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
2 Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran

Correspondence Address:
Habibollah Dadgar
Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad
Iran

Prostate-specific membrane antigen (PSMA) labeled with68Ga routinely used with higher sensibility and specificity than other radiotracers for detection of low and high grades of prostate cancer using positron emission tomography (PET)-computed tomography.68Ge/68Ga generators are generally used with automated modules for the syntheses of68Ga radiopharmaceuticals. The aim of the current study is to describe the procedures for labeling PSMA with radiotracers and their standard QC tests. The automated synthesis method for68Ga-PSMA-11 was taken and set of a quality control based on chromatographic and spectrometric methods used to determine radiochemical and radionuclide purity of the radiolabeled compound. Meanwhile, high-performance liquid chromatography and rainbow trail Lutheran camp are the best choices after stability tests for assessment of radiochemical purity at the optimized conditions. The clinical utility of the synthesized radiopharmaceuticals was ascertained by performing PET scans in human patients.


How to cite this article:
Assadi M, Dadgar H. Quality control and GMP synthesis of68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer.World J Nucl Med 2020;19:93-98


How to cite this URL:
Assadi M, Dadgar H. Quality control and GMP synthesis of68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer. World J Nucl Med [serial online] 2020 [cited 2020 Aug 7 ];19:93-98
Available from: http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=2;spage=93;epage=98;aulast=Assadi;type=0